• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by Inspira Technologies Oxy B.H.N. Ltd.

    9/16/25 5:00:17 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care
    Get the next $IINN alert in real time by email
    424B5 1 ea0257603-424b5_inspira.htm PROSPECTUS SUPPLEMENT

     

    Filed Pursuant to Rule 424(b)(5)

    Registration No. 333-266748

     

    AMENDMENT NO. 3 DATED SEPTEMBER 16, 2025

    To Prospectus Supplements dated July 1, 2025, April 10, 2025 and March 14, 2025

    (to Prospectus dated August 18, 2022)

     

     

     

    Up to $9,985,579

    Ordinary Shares

     

    This Amendment No. 3, or the Amendment, amends and supplements the information in the prospectus, dated August 18, 2022, filed with the Securities and Exchange Commission as a part of our registration statement on Form F-3 (File No. 333-266748), as previously supplemented by our prospectus supplement dated March 14, 2025, our prospectus supplement dated April 10, 2025 and our prospectus supplement dated July 1, 2025, or, collectively, the Prior Prospectus, relating to the offer and sale of up to $7,117,720 of our ordinary shares, no par value, or Ordinary Shares, pursuant to the sales agreement, or the Sales Agreement, with A.G.P./Alliance Global Partners, or A.G.P., dated March 14, 2025. This Amendment should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This Amendment is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus and any future amendments or supplements thereto.

     

    We are filing this Amendment to supplement and amend, as of September 16, 2025, the Prior Prospectus to increase the maximum aggregate offering price of our Ordinary Shares that may be offered, issued and sold under the Sales Agreement from $7,117,720 to $9,985,579. Accordingly, we may offer and sell Ordinary Shares having a maximum aggregate offering price of up to $9,985,579.

     

    Sales of our Ordinary Shares, if any, under the Prior Prospectus and this Amendment, may be made in sales deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act. A.G.P. is not required to sell any specific number or dollar amount of securities but will act as a sales agent on a best efforts basis and will use commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between A.G.P. and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. To date, we have sold an aggregate of $4,701,062 of our Ordinary Shares pursuant to the Sales Agreement.

     

    A.G.P. will be entitled to compensation at a commission rate of 3.0% of the gross sales price per share sold pursuant to the terms of the Sales Agreement. See “Plan of Distribution” beginning on page S-12 of the Prior Prospectus for additional information regarding the compensation to be paid to A.G.P. In connection with the sale of our Ordinary Shares on our behalf, A.G.P. will be deemed to be an “underwriter” within the meaning of the Securities Act, and the compensation of the A.G.P. will be deemed to be underwriting commissions or discounts. We also have agreed to provide indemnification and contribution to A.G.P. with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.

     

    Our Ordinary Shares are listed on The Nasdaq Capital Market, or Nasdaq, under the symbol “IINN”. On September 15, 2025, the last reported sale price of our Ordinary Shares on Nasdaq was $1.17 per Ordinary Share.

     

    The aggregate market value of our Ordinary Shares held by non-affiliates as of September 16, 2025, pursuant to General Instruction I.B.5 of Form F-3 is $44,059,923 which was calculated based on 32,567,244 Ordinary Shares outstanding held by non-affiliates and at a price of $1.47 per Ordinary Share, the closing price of our Ordinary Shares on July 17, 2025. We have sold an aggregate of approximately $4,701,062 of securities pursuant to General Instruction I.B.5. of Form F-3 during the 12-calendar month calendar period that ends on, and includes, the date of this Amendment and, as a result, the capacity to sell securities under our Form F-3 Registration Statement pursuant to General Instruction I.B.5. is currently $9,985,579.

     

    Investing in our Ordinary Shares involves risk. See “Risk Factors” beginning on page S-4 of the Prior Prospectus and in the documents incorporated by reference into the Prior Prospectus for a discussion of information that should be considered in connection with an investment in our Ordinary Shares.

     

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prior Prospectus, this Amendment or the accompanying prospectus. Any representation to the contrary is a criminal offense.

     

    A.G.P.

     

    The date of this prospectus supplement is September 16, 2025.

     

    Get the next $IINN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IINN

    DatePrice TargetRatingAnalyst
    11/1/2021$9.00 → $10.00Buy
    Aegis Capital
    8/26/2021$9.00Buy
    Aegis Capital
    More analyst ratings

    $IINN
    SEC Filings

    View All

    SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

    6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    10/1/25 8:00:39 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

    6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    9/18/25 8:00:09 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Inspira Technologies Oxy B.H.N. Ltd.

    424B5 - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    9/16/25 5:00:17 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update

    RA'ANANA, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the six-month period ended June 30, 2025, and issued a business update. "The first half of 2025 represents a pivotal transformation for Inspira as we have successfully transitioned from being a development-stage company to commencing commercial execution. Our technology is now saving lives in premier U.S. hospitals while generating growing commercial interest globally," said Dagi Ben-Noon, Chief Executive Officer of Inspira. "With $49.5 millio

    10/1/25 8:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira to Unveil HYLA™ Real-Time Blood Sensor at U.S. ELSO; 97.35% Accuracy Confirmed

    RA'ANANA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it will present its HYLA blood sensor ("HYLA") to the global medical community for the first time. The presentation will take place at the U.S. ELSO Annual Conference in Washington, D.C., between September 27–30, 2025. This official unveiling follows the Company's recent announcement of the HYLA sensor's performance data, which demonstrated 97.35% accuracy compared to standard blood gas analyzers. The ELSO conference, widely regarded as the largest an

    9/18/25 8:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Announces 97.3% Accuracy Results for HYLA™ Blood Sensor, Advancing Toward FDA Submission for Clearance

    RA'ANANA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced pivotal results for its HYLA blood sensor, achieving 97.35% accuracy in its latest performance testing phase that will support its upcoming U.S. Food and Drug Administration ("FDA") submission. These results represent a significant advancement from the initial data obtained in a clinical study, as announced on March 4, 2025. The clinical study from March, conducted at a medical center ranked among the world's leading hospitals, provided validation fo

    9/11/25 9:30:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital reiterated coverage on Inspira Technologies Oxy with a new price target

    Aegis Capital reiterated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $10.00 from $9.00 previously

    11/1/21 12:39:26 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Aegis Capital initiated coverage on Inspira Technologies Oxy with a new price target

    Aegis Capital initiated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $9.00

    8/26/21 10:05:11 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Leadership Updates

    Live Leadership Updates

    View All

    PESG Report: Inspira Technologies Strengthens its AI-Powered Blood Sensor with new Capabilities, Intends to Share Clinical Findings Soon

    Inspira Technologies* advancement of its AI-powered blood monitoring technology comes amid robust growth in medical technology M&A, with Q3 2024 seeing 275 deals worth $34 billion - a 35% increase year-over-year. The integration of this new oxygenation indicator strengthens the Company's position in both the $2.5 billion blood gas analysis market and, through the FDA-cleared INSPIRA ART100 system, the $19 billion mechanical ventilation market. With clinical evaluations of the HYLA blood sensor underway at Sheba Medical Center and preliminary results reportedly expected in the near future, the Company continues to execute its strategy of combining AI-enhanced monitoring capabilities with inn

    2/6/25 8:27:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira™ Announces the Appointment of Tal Parnes as the New Chairman of the Board, Bringing Vast Experience in the Medical Technology and Pharmaceutical Sectors

    RA'ANANA, Israel, Jan. 21, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced the appointment of Mr. Tal Parnes as the new chairman of the board of directors, effective February 1, 2025.     Mr. Parnes brings a wealth of experience and expertise to his new role at Inspira. With a distinguished career spanning over three decades in the technology sector, with a special focus in the medical technology and pharmaceutical industries, Mr. Parnes has consistently demonstrated exceptional leadership and strategic vision. As a serial entrepreneur, Parnes has demonstrated

    1/21/25 8:30:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    In Preparation for FDA Clearance and Device Deployment, Inspira has Appointed Dr. Dan Gorfil, to Medical Advisory Board

    RA'ANANA, Israel, Dec. 11, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board. Dr. Gorfil is a distinguished specialist in cardiac surgery and intensive care medicine. Dr. Gorfil is both the head of the Cardiothoracic Surgery Intensive Care Unit and the Extracorporeal Membrane Oxygenation program at the Department of Cardiothoracic Surgery at Rabin Medical Center, Israel. Dr. Gorfil's expertise are expected to significantly contribute to the

    12/11/23 9:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Financials

    Live finance-specific insights

    View All

    Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update

    RA'ANANA, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the six-month period ended June 30, 2025, and issued a business update. "The first half of 2025 represents a pivotal transformation for Inspira as we have successfully transitioned from being a development-stage company to commencing commercial execution. Our technology is now saving lives in premier U.S. hospitals while generating growing commercial interest globally," said Dagi Ben-Noon, Chief Executive Officer of Inspira. "With $49.5 millio

    10/1/25 8:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates

    Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA'ANANA, Israel, March 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2024, and provided a corporate update. Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: "2024 was a transformative year for Inspira, marked by significant technological advancements and a major regulatory milestone. We successfully obtained 510(k) clearance from the Food and Drug Administration ("FDA") for our INSPIRA™ ART100 system an

    3/11/25 8:30:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira™ Announces Business Plan Targets

    Company to aggressively promote INSPIRA™ ART100 in the U.S. and additional markets following FDA clearance, as well as accelerate plans for ground-breaking INSPIRA™ ART (Gen2) RA'ANANA, Israel, June 20, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), (NASDAQ:IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced today that the Company's President and co-founder, Mr. Joe Hayon, presented a business plan with targets for the Company's next-generation technologies on a Company conference call today.     On the call, Inspira unveiled plans to build an opportunity for a share of the $19 billion mechanical ventilation market. Inspira's

    6/20/24 9:25:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd.

    SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    11/14/24 4:08:42 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Inspira Technologies Oxy B.H.N. Ltd.

    SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    2/14/24 3:40:01 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd. (Amendment)

    SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    2/12/24 4:05:09 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care